Should we Change our Therapeutic Management of Type 2 Diabetes based on Accumulating Evidence?

Should we Change our Therapeutic Management of Type 2 Diabetes based on Accumulating Evidence?

Mona M. Salem

Contact

Usama AA Sharaf El Din

Contact

Dina O Abdulazim

Contact

Cairo University

Should we Change our Therapeutic Management of Type 2 Diabetes based on Accumulating Evidence?

Article Fingerprint

ReserarchID

097P8

Should we Change our Therapeutic Management of Type 2 Diabetes based on Accumulating Evidence? Banner

AI TAKEAWAY

Connecting with the Eternal Ground

References

152 Cites in Article

Reference Format

F B Hu,A Satija,J Manson (2015). Curbing the Diabetes Pandemic: The Need for Global Policy Solutions.
(2016). World health organization Global report on diabetes.
Julie Ingelfinger,Clifford Rosen (2019). Clinical Credence — SGLT2 Inhibitors, Diabetes, and Chronic Kidney Disease.
Rao Kondapally Seshasai,S Kaptoge,S Thompson,A,Di Angelantonio,E Gao,P Sarwar,N (2011). Diabetes mellitus, fasting glucose, and risk of cause-specific death.
Lidia Loukine,Chris Waters,Bernard Choi,Joellyn Ellison (2012). Impact of diabetes mellitus on life expectancy and health-adjusted life expectancy in Canada.
Y Zheng,M He,N Congdon (2012). The worldwide epidemic of diabetic retinopathy.
Anjali Deshpande,Marcie Harris-Hayes,Mario Schootman (2008). Epidemiology of Diabetes and Diabetes-Related Complications.
Sean Candrilli,Keith Davis,Hong Kan,Melanie Lucero,Matthew Rousculp (2007). Prevalence and the associated burden of illness of symptoms of diabetic peripheral neuropathy and diabetic retinopathy.
Linda Humphrey,David Ballard,Peter Frohnert,Chu-Pin Chu,W O'fallon,Pasquale Palumbo (1989). Chronic Renal Failure in Non-Insulin-Dependent Diabetes Mellitus.
R Defronzo (1995). Diabetic nephropathy: etiologic and therapeutic considerations.
G A Nichols,T A Hillier,J Erbey,J Brown (2001). Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors.
Melec Zeadin,Christina Petlura,Geoff Werstuck (2013). Molecular Mechanisms Linking Diabetes to the Accelerated Development of Atherosclerosis.
R Chen,B Ovbiagele,W Feng (2016). Diabetes and Stroke: Epidemiology, Pathophysiology, Pharmaceuticals and Outcomes.
Milton Packer (2017). Activation and Inhibition of Sodium-Hydrogen Exchanger Is a Mechanism That Links the Pathophysiology and Treatment of Diabetes Mellitus With That of Heart Failure.
K Maiese (2015). New Insights for Oxidative Stress and Diabetes Mellitus.
Wei Cai,Xi-Mei Duan,Ying Liu,Jiao Yu,Yun-Liang Tang,Ze-Lin Liu,Shan Jiang,Chun-Ping Zhang,Jian-Ying Liu,Ji-Xiong Xu (2017). Uric Acid Induces Endothelial Dysfunction by Activating the HMGB1/RAGE Signaling Pathway.
James List,Jean Whaley (2011). Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans.
The Diabetes,Control,Complications Trial,Research Group (1993). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.
Diabetes Uk Prospective,( Study,Ukpds) Group (1998). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).
Kausik Ray,Sreenivasa Seshasai,Shanelle Wijesuriya,Rupa Sivakumaran,Sarah Nethercott,David Preiss,Sebhat Erqou,Naveed Sattar (2009). Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials.
Diabetes Uk Prospective,( Study,Ukpds) Group (1998). Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).
Alan Garber,Martin Abrahamson,Joshua Barzilay,Lawrence Blonde,Zachary Bloomgarden,Michael Bush,Samuel Dagogo-Jack,Ralph Defronzo,Daniel Einhorn,Vivian Fonseca,Jeffrey Garber,W Garvey,George Grunberger,Yehuda Handelsman,Irl Hirsch,Paul Jellinger,Janet Mcgill,Jeffrey Mechanick,Paul Rosenblit,Guillermo Umpierrez (2018). Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2018 Executive Summary.
M Røder (2018). Major adverse cardiovascular event reduction with GLP-1 and SGLT2 agents: evidence and clinical potential.
C Triplitt,C Solis-Herrera,E Cersosimo,M Abdul-Ghani,Ralph Defronzo (2015). Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus.
Masarori Wakisaka,Tetsuhiko Nagao (2017). Sodium glucose cotransporter 2 in mesangial cells and retinal pericytes and its implications for diabetic nephropathy and retinopathy.
R Furchgott,J Zawadzki (1980). The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine.
Denis Roy,Mylène Perreault,André Marette (1998). Insulin stimulation of glucose uptake in skeletal muscles and adipose tissues in vivo is NO dependent.
H Wang,A X Wang,E Barrett (2011). Caveolin-1 is required for vascular endothelial insulin uptake.
Cathryn Kolka,Richard Bergman (2013). The endothelium in diabetes: Its role in insulin access and diabetic complications.
Sherene Shenouda,Michael Widlansky,Kai Chen,Guoquan Xu,Monika Holbrook,Corey Tabit,Naomi Hamburg,Alissa Frame,Tara Caiano,Matthew Kluge,Mai-Ann Duess,Aaron Levit,Brian Kim,Mor-Li Hartman,Lija Joseph,Orian Shirihai,Joseph Vita (2011). Altered Mitochondrial Dynamics Contributes to Endothelial Dysfunction in Diabetes Mellitus.
Arpeeta Sharma,Pascal Bernatchez,Judy De Haan (2012). Targeting Endothelial Dysfunction in Vascular Complications Associated with Diabetes.
He Chang,Xin Gao,Rachel Nepomuceno,Shaoshan Hu,Dandan Sun (2015). Na+/H+ exchanger in the regulation of platelet activation and paradoxical effects of cariporide.
Zeynep Osar,Tülay Samanci,Gülderen Demirel,Taner Damci,Hasan Ilkova (2004). Nicotinamide Effects Oxidative Burst Activity of Neutrophils in Patients with Poorly Controlled Type 2 Diabetes Mellitus.
Synne Hansen,Ellen Aasum,Anne Hafstad (2017). The role of NADPH oxidases in diabetic cardiomyopathy.
Sumon Roy,Dongjoon Kim,Cristina Hernández,Rafael Simó,Sayon Roy (2015). Beneficial effects of fenofibric acid on overexpression of extracellular matrix components, COX-2, and impairment of endothelial permeability associated with diabetic retinopathy.
Amira Othman,Saif Ahmad,Sylvia Megyerdi,Rene Mussell,Karishma Choksi,Krishna Maddipati,Ahmed Elmarakby,Nasser Rizk,Mohamed Al-Shabrawey (2013). 12/15-Lipoxygenase-Derived Lipid Metabolites Induce Retinal Endothelial Cell Barrier Dysfunction: Contribution of NADPH Oxidase.
Y Zheng,M He,N Congdon (2012). The worldwide epidemic of diabetic retinopathy.
J Wada,H Makino (2013). Inflammation and the pathogenesis of diabetic nephropathy.
Bingmei Yang,Andrea Hodgkinson,Peter Oates,Beverley Millward,Andrew Demaine (2008). High glucose induction of DNA-binding activity of the transcription factor NFκB in patients with diabetic nephropathy.
Hunjoo Ha,Mi Yu,Yoon Choi,Masanori Kitamura,Hi Lee (2002). Role of High Glucose-Induced Nuclear Factor-κB Activation in Monocyte Chemoattractant Protein-1 Expression by Mesangial Cells.
C Park,J Kim,J H Lee,Y S Kim,H Ahn,Y Shin (2000). High glucose-induced intercellular adhesion molecule-1 (ICAM-1) expression through an osmotic effect in rat mesangial cells is PKC-NF-κ B-dependent.
N Kashihara,Y Haruna,V Kondeti,Y Kanwar (2010). Oxidative stress in diabetic nephropathy.
D Jalal,C Rivard,R J Johnson,K Maahs D M, Mcfann,M Rewers,J Snell-Bergeon (2010). Serum uric acid levels predict the development of albuminuria over 6 years in patients with type 1 diabetes: findings from the Coronary Artery Calcification in Type 1 Diabetes study.
Linda Ficociello,Elizabeth Rosolowsky,Monika Niewczas,Nicholas Maselli,Janice Weinberg,Ann Aschengrau,John Eckfeldt,Robert Stanton,Andrzej Galecki,Alessandro Doria,James Warram,Andrzej Krolewski (2010). High-Normal Serum Uric Acid Increases Risk of Early Progressive Renal Function Loss in Type 1 Diabetes.
P Hovind,P Rossing,L Tarnow,R J Johnson,H Parving (2009). Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study.
Dandan Yan,Yinfang Tu,Feng Jiang,Jie Wang,Rong Zhang,Xue Sun,Tao Wang,Shiyun Wang,Yuqian Bao,Cheng Hu,Weiping Jia (2015). Uric Acid Is Independently Associated with Diabetic Kidney Disease: A Cross-Sectional Study in a Chinese Population.
S De Cosmo,F Viazzi,A Pacilli,C Giorda,A Ceriello,S Gentile,G Russo,M C Rossi,A Nicolucci,P Guida,D Feig,R J Johnson,R Pontremoli (2015). Serum Uric Acid and Risk of CKD in Type 2 Diabetes.
Keita Takae,Masaharu Nagata,Jun Hata,Naoko Mukai,Yoichiro Hirakawa,Daigo Yoshida,Hiro Kishimoto,Kazuhiko Tsuruya,Takanari Kitazono,Yutaka Kiyohara,Toshiharu Ninomiya (2016). Serum Uric Acid as a Risk Factor for Chronic Kidney Disease in a Japanese Community – The Hisayama Study –.
Vendula Bartáková,Katarína Kuricová,Lukáš Pácal,Zuzana Nová,Veronika Dvořáková,Martina Švrčková,Denisa Malúšková,Ivana Svobodová,Jitka Řehořová,Jan Svojanovský,Jindřich Olšovský,Jana Bělobrádková,Kateřina Kaňková (2016). Hyperuricemia contributes to the faster progression of diabetic kidney disease in type 2 diabetes mellitus.
Peng Liu,Yingying Chen,Bin Wang,Fengmei Zhang,Debao Wang,Yangang Wang (2015). Allopurinol treatment improves renal function in patients with type 2 diabetes and asymptomatic hyperuricemia: 3‐year randomized parallel‐controlled study.
Tahir Kanji,Mandark Gandhi,Catherine Clase,Robert Yang (2015). Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis.
Erlandsson Harris,H Andersson,U (2004). Mini-review: The nuclear protein HMGB1 as a proinflammatory mediator.
Wei Cai,Xi-Mei Duan,Ying Liu,Jiao Yu,Yun-Liang Tang,Ze-Lin Liu,Shan Jiang,Chun-Ping Zhang,Jian-Ying Liu,Ji-Xiong Xu (2017). Uric Acid Induces Endothelial Dysfunction by Activating the HMGB1/RAGE Signaling Pathway.
Ji Wang,Tianqiang Qin,Jianrong Chen,Yulin Li,Ling Wang,He Huang,Jing Li (2014). Hyperuricemia and Risk of Incident Hypertension: A Systematic Review and Meta-Analysis of Observational Studies.
T Vilsbøll,J Holst (2004). Incretins, insulin secretion and Type 2 diabetes mellitus.
S Kalra (2013). Glucagon-like peptide-1 receptors agonists (GLP1 RA).
S A Ross,J Ekoé (2010). Incretin agents in type 2 diabetes.
S Inzucchi,R Bergenstal,J Buse,M Diamant,E Ferrannini,M Nauck (2015). Management of hyperglycemia in type 2 diabetes, 2015: a patientcentered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.
Jacob Sivertsen,Jaya Rosenmeier,Jens Holst,Tina Vilsbøll (2012). The effect of glucagon-like peptide 1 on cardiovascular risk.
Daniel Drucker (2016). The Cardiovascular Biology of Glucagon-like Peptide-1.
J Lepore,E Olson,L Demopoulos,T3 Haws,Z4 Fang,A Barbour (2016). Effects of the novel long-acting GLP-1 agonist, albiglutide, on cardiac function, cardiac metabolism, and exercise capacity in patients with chronic heart failure and reduced ejection fraction.
Kenneth Margulies,Adrian Hernandez,Margaret Redfield,Michael Givertz,Guilherme Oliveira,Robert Cole,Douglas Mann,David Whellan,Michael Kiernan,G Felker,Steven Mcnulty,Kevin Anstrom,Monica Shah,Eugene Braunwald,Thomas Cappola (2016). Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction.
M Pfeffer,B Claggett,R Diaz,K Dickstein,H Gerstein,L Køber (2015). Lixisenatide in patients with type 2 diabetes and acute coronary syndrome.
Steven Marso,Gilbert Daniels,Kirstine Brown-Frandsen,Peter Kristensen,Johannes Mann,Michael Nauck,Steven Nissen,Stuart Pocock,Neil Poulter,Lasse Ravn,William Steinberg,Mette Stockner,Bernard Zinman,Richard Bergenstal,John Buse (2016). Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven Marso,Stephen Bain,Agostino Consoli,Freddy Eliaschewitz,Esteban Jódar,Lawrence Leiter,Ildiko Lingvay,Julio Rosenstock,Jochen Seufert,Mark Warren,Vincent Woo,Oluf Hansen,Anders Holst,Jonas Pettersson,Tina Vilsbøll (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Holman R R,M A Bethel,R J Mentz,V P Thompson,Y Lokhnygina,J Buse (2017). Effects of onceweekly exenatide on cardiovascular outcomes in type 2 diabetes.
M Røder (2018). Major adverse cardiovascular event reduction with GLP-1 and SGLT2 agents: evidence and clinical potential.
Keith Ferdinand,Fady Botros,Charles Atisso,Philip Sager (2016). Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
Merlin Thomas (2017). The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes.
Annayya Aroor,Marcin Zuberek,Cornel Duta,Alex Meuth,James Sowers,Adam Whaley-Connell,Ravi Nistala (2016). Angiotensin II Stimulation of DPP4 Activity Regulates Megalin in the Proximal Tubules.
Adriana Girardi,Lívia Fukuda,Luciana Rossoni,Gerhard Malnic,Nancy Rebouças (2008). Dipeptidyl peptidase IV inhibition downregulates Na <sup>+</sup> -H <sup>+</sup> exchanger NHE3 in rat renal proximal tubule.
Marcel Muskiet,Mark Smits,Linde Morsink,Michaela Diamant (2014). The gut–renal axis: do incretin-based agents confer renoprotection in diabetes?.
Benjamin Scirica,Deepak Bhatt,Eugene Braunwald,P Steg,Jaime Davidson,Boaz Hirshberg,Peter Ohman,Robert Frederich,Stephen Wiviott,Elaine Hoffman,Matthew Cavender,Jacob Udell,Nihar Desai,Ofri Mosenzon,Darren Mcguire,Kausik Ray,Lawrence Leiter,Itamar Raz (2013). Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus.
J A Udell,D L Bhatt,E Braunwald,M Cavender,O Mosenzon,P Steg (2015). Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial.
Eun Lee,J Kim,J Lee,M H Song,H K Ghee,J Kang,Y S (2016). DA-1229, a dipeptidyl peptidase IV inhibitor, protects against renal injury by preventing podocyte damage in an animal model of progressive renal injury.
Lorenzo Glorie,Anja Verhulst,Veerle Matheeussen,Lesley Baerts,Joanna Magielse,Nina Hermans,Patrick D'haese,Ingrid De Meester,Annelies De Beuf (2012). DPP4 inhibition improves functional outcome after renal ischemia-reperfusion injury.
J Holst,C F Deacon (2005). Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors.
Ravi Nistala,Virginia Savin (2017). Diabetes, hypertension, and chronic kidney disease progression: role of DPP4.
C Deacon (2005). What do we know about the secretion and degradation of incretin hormones?.
M De,I Korom,S Van,D J Scharpe,S (1999). CD26, let it cut or cut it down.
C Klemann,L Wagner,M Stephan,S Von Hörsten (2016). Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system.
Daniela Lamers,Susanne Famulla,Nina Wronkowitz,Sonja Hartwig,Stefan Lehr,D Ouwens,Kristin Eckardt,Jean Kaufman,Mikael Ryden,Stefan Müller,Franz-Georg Hanisch,Johannes Ruige,Peter Arner,Henrike Sell,Juergen Eckel (2011). Dipeptidyl Peptidase 4 Is a Novel Adipokine Potentially Linking Obesity to the Metabolic Syndrome.
Helena Chowdhury,Jelena Velebit,Nataša Radić,Vito Frančič,Marko Kreft,Robert Zorec (2016). Hypoxia Alters the Expression of Dipeptidyl Peptidase 4 and Induces Developmental Remodeling of Human Preadipocytes.
Diana Röhrborn,Jürgen Eckel,Henrike Sell (2014). Shedding of dipeptidyl peptidase 4 is mediated by metalloproteases and up‐regulated by hypoxia in human adipocytes and smooth muscle cells.
Adriana Girardi,Brenda Degray,Tamas Nagy,Daniel Biemesderfer,Peter Aronson (2001). Association of Na+-H+ Exchanger Isoform NHE3 and Dipeptidyl Peptidase IV in the Renal Proximal Tubule.
C Girardi,L Fukuda,L Rossoni,G Malnic,N A Reboucas (2008). Dipeptidyl peptidase IV inhibition downregulates Na+ -H+ exchanger NHE3 in rat renal proximal tubule.
Annayya Aroor,Marcin Zuberek,Cornel Duta,Alex Meuth,James Sowers,Adam Whaley-Connell,Ravi Nistala (2005). Angiotensin II Stimulation of DPP4 Activity Regulates Megalin in the Proximal Tubules.
G Dekan,A Miettinen,E Schnabel,M Farquhar (1990). Binding of monoclonal antibodies to glomerular endothelium, slit membranes, and epithelium after in vivo injection. Localization of antigens and bound IgGs by immunoelectron microscopy.
M L Alter,O Ott I M, Von W K, Tsuprykov,Y Sharkovska,K Krause-Relle (2012). DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy.
O Mosenzon,G Leibowitz,D Bhatt,A Cahn,B Hirshberg,C Wei (2017). Effect of Saxagliptin on renal outcomes in the SAVOR-TIMI 53 Trial.
Jan Cornel,George Bakris,Susanna Stevens,Michael Alvarsson,Willem Bax,Lee-Ming Chuang,Samuel Engel,Renato Lopes,Darren Mcguire,Axel Riefflin,Helena Rodbard,Isaac Sinay,Tsvetalina Tankova,Julio Wainstein,Eric Peterson,Rury Holman (2016). Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS.
William White,Christopher Cannon,Simon Heller,Steven Nissen,Richard Bergenstal,George Bakris,Alfonso Perez,Penny Fleck,Cyrus Mehta,Stuart Kupfer,Craig Wilson,William Cushman,Faiez Zannad (2013). Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes.
Per‐henrik Groop,Mark Cooper,Vlado Perkovic,Berthold Hocher,Keizo Kanasaki,Masakazu Haneda,Guntram Schernthaner,Kumar Sharma,Robert Stanton,Robert Toto,Jessica Cescutti,Maud Gordat,Thomas Meinicke,Audrey Koitka‐weber,Sandra Thiemann,Maximilian Von Eynatten (2017). Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized <scp>MARLINA</scp> ‐ <scp>T2D</scp> trial.
Per-Henrik Groop,Mark Cooper,Vlado Perkovic,Angela Emser,Hans-Juergen Woerle,Maximilian Von Eynatten (2013). Linagliptin Lowers Albuminuria on Top of Recommended Standard Treatment in Patients With Type 2 Diabetes and Renal Dysfunction.
Keizo Kanasaki,Sen Shi,Megumi Kanasaki,Jianhua He,Takako Nagai,Yuka Nakamura,Yasuhito Ishigaki,Munehiro Kitada,Swayam Srivastava,Daisuke Koya (2014). Linagliptin-Mediated DPP-4 Inhibition Ameliorates Kidney Fibrosis in Streptozotocin-Induced Diabetic Mice by Inhibiting Endothelial-to-Mesenchymal Transition in a Therapeutic Regimen.
S Shi,S P Srivastava,M Kanasaki,J He,M Kitada,T Nagai (2015). Interactions of DPP-4 and integrin β1 influences endothelial-to-mesenchymal transition.
C Lee,; S 1,Y Kim,S G 4 ; Lee (2016). Dipeptidyl Peptidase-4 Inhibitor Increases Vascular Leakage in Retina through VE-cadherin Phosphorylation.
Y Chung,S Park,J Kim,J H ; Kim,Packer (2016). M. Have dipeptidyl peptidase-4 inhibitors ameliorated the vascular complications of type 2 diabetes in large-scale trials? The potential confounding effect of stem-cell chemokines.
V Ferdousie,M Mohammadi,G Hassanshahi,H Khorramdelazad,S K Falahati-Pour,M Mirzaei (2017). Serum CXCL10 and CXCL12 chemokine levels are associated with the severity of coronary artery disease and coronary artery occlusion.
Murthy Darisipudi,Onkar Kulkarni,Sufyan Sayyed,Mi Ryu,Adriana Migliorini,Costanza Sagrinati,Eliana Parente,Axel Vater,Dirk Eulberg,Sven Klussmann,Paola Romagnani,Hans-Joachim Anders (2011). Dual Blockade of the Homeostatic Chemokine CXCL12 and the Proinflammatory Chemokine CCL2 Has Additive Protective Effects on Diabetic Kidney Disease.
Jason Butler,Steven Guthrie,Mehmet Koc,Aqeela Afzal,Sergio Caballero,H L Brooks,Robert Mames,Mark Segal,Maria Grant,Edward Scott (2005). SDF-1 is both necessary and sufficient to promote proliferative retinopathy.
R Defronzo,M Hompesch,S Kasichayanula,X Liu,Y Hong,M Pfister (2013). Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes.
E Van Bommel,M Muskiet,L Tonneijck,M H Kramer,M Nieuwdorp,D H Van Raalte,Sglt2 (2017). Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome.
Yukihiro Chino,Yoshishige Samukawa,Soichi Sakai,Yasuhiro Nakai,Jun‐ichi Yamaguchi,Takeo Nakanishi,Ikumi Tamai (2014). SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria.
Petter Bjornstad,Miguel Lanaspa,Takuji Ishimoto,Tomoki Kosugi,Shinji Kume,Diana Jalal,David Maahs,Janet Snell-Bergeon,Richard Johnson,Takahiko Nakagawa (2015). Fructose and uric acid in diabetic nephropathy.
M Cristóbal-García,F García-Arroyo,E Tapia,H Osorio,A Arellano-Buendía,M Madero (2015). Renal oxidative stress induced by long-term hyperuricemia alters mitochondrial function and maintains systemic hypertension.
Eun-Sun Ryu,Mi Kim,Hyun-Soo Shin,Yang-Hee Jang,Hack Choi,Inho Jo,Richard Johnson,Duk-Hee Kang (2013). Uric acid-induced phenotypic transition of renal tubular cells as a novel mechanism of chronic kidney disease.
Ying Yang,Dong-Mei Zhang,Jia-Hui Liu,Lin-Shui Hu,Qiao-Chu Xue,Xiao-Qin Ding,Ling-Dong Kong (2015). Wuling San protects kidney dysfunction by inhibiting renal TLR4/MyD88 signaling and NLRP3 inflammasome activation in high fructose-induced hyperuricemic mice.
Leonard Hayflick (2003). Living forever and dying in the attempt.
Kento Kitada,Daisuke Nakano,Hiroyuki Ohsaki,Hirofumi Hitomi,Tohru Minamino,Junichi Yatabe,Robin Felder,Hirohito Mori,Tsutomu Masaki,Hiroyuki Kobori,Akira Nishiyama (2014). Hyperglycemia causes cellular senescence via a SGLT2- and p21-dependent pathway in proximal tubules in the early stage of diabetic nephropathy.
U Panchapakesan,K Pegg,S Gross,M Komala,H Mudaliar,J Forbes (2013). Effects of SGLT2 inhibition in human kidney proximal tubular cells-renoprotection in diabetic nephropathy?.
A Ojima,T Matsui,Y Nishino,N Nakamura,S Yamagishi (2015). Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis.
N Terami,D Ogawa,H Tachibana,T Hatanaka,J Wada,A Nakatsuka (2014). Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice.
Christina Cicerchi,Nanxing Li,James Kratzer,Gabriela Garcia,Carlos Roncal‐jimenez,Katsuyuki Tanabe,Brandi Hunter,Christopher Rivard,Yuri Sautin,Eric Gaucher,Richard Johnson,Miguel Lanaspa (2014). Uric acid‐dependent inhibition of AMP kinase induces hepatic glucose production in diabetes and starvation: evolutionary implications of the uricase loss in hominids.
Christoph Wanner,Silvio Inzucchi,John Lachin,David Fitchett,Maximilian Von Eynatten,Michaela Mattheus,Odd Johansen,Hans Woerle,Uli Broedl,Bernard Zinman (2016). Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
C Zoja,A Benigni,G Remuzzi (2014). The Nrf2 pathway in the progression of renal disease.
Manuel Matzinger,Katrin Fischhuber,Elke Heiss (2017). Activation of Nrf2 signaling by natural products-can it alleviate diabetes?.
Joshua David,William Rifkin,Piul Rabbani,Daniel Ceradini (2017). The Nrf2/Keap1/ARE Pathway and Oxidative Stress as a Therapeutic Target in Type II Diabetes Mellitus.
Jiménez-Osorio A S González-Reyes,S Pedraza-Chaverri,J (2015). Natural Nrf2 activators in diabetes.
Xiuli Zhang,Hui He,Dan Liang,Yan Jiang,Wei Liang,Zhi-Hong Chi,Jianfei Ma (2016). Protective Effects of Berberine on Renal Injury in Streptozotocin (STZ)-Induced Diabetic Mice.
M Raish,Ahmad Jan,B L Alkharfy,K Ansari,M Mohsin,K (2016). Momordica charantia polysaccharides mitigate the progression of STZ induced diabetic nephropathy in rats.
Qingqiao Yin,Yuanyu Xia,Guan Wang (2016). Sinomenine alleviates high glucose-induced renal glomerular endothelial hyperpermeability by inhibiting the activation of RhoA/ROCK signaling pathway.
Zahra Bahadoran,Maryam Tohidi,Pantea Nazeri,Mahya Mehran,Fereidoun Azizi,Parvin Mirmiran (2012). Effect of broccoli sprouts on insulin resistance in type 2 diabetic patients: a randomized double-blind clinical trial.
P Brasnyó,G Molnár,M Mohás,L Markó,B Laczy,J Cseh (2011). Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients.
Kian Goh,Hwei Lee,Dawn Lau,Wilma Supaat,Yiong Chan,Angela Koh (2014). Effects of Resveratrol in Patients with Type 2 Diabetes Mellitus on Skeletal Muscle SIRT1 Expression and Energy Expenditure.
Sony Thazhath,Tongzhi Wu,Michelle Bound,Helen Checklin,Scott Standfield,Karen Jones,Michael Horowitz,Christopher Rayner (2016). Administration of resveratrol for 5 wk has no effect on glucagon-like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial.
João Tomé-Carneiro,Manuel Gonzálvez,Mar Larrosa,María Yáñez-Gascón,Francisco García-Almagro,José Ruiz-Ros,María García-Conesa,Francisco Tomás-Barberán,Juan Espín (2012). One-Year Consumption of a Grape Nutraceutical Containing Resveratrol Improves the Inflammatory and Fibrinolytic Status of Patients in Primary Prevention of Cardiovascular Disease.
João Tomé-Carneiro,Mar Larrosa,María Yáñez-Gascón,Alberto Dávalos,Judit Gil-Zamorano,Manuel Gonzálvez,Francisco García-Almagro,José Ruiz Ros,Francisco Tomás-Barberán,Juan Espín,María-Teresa García-Conesa (2013). One-year supplementation with a grape extract containing resveratrol modulates inflammatory-related microRNAs and cytokines expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease.
S Bo,V Ponzo,G Ciccone,A Evangelista,F Saba,I Goitre,M Procopio,G Pagano,M Cassader,R Gambino (2016). Six months of resveratrol supplementation has no measurable effect in type 2 diabetic patients. A randomized, double blind, placebo-controlled trial.
R Wong,R Nealon,A Scholey,P Howe (2016). Low dose resveratrol improves cerebrovascular function in type 2 diabetes mellitus.
Wong R H,D Raederstorff,P Howe (2016). Acute Resveratrol Consumption Improves Neurovascular Coupling Capacity in Adults with Type 2 Diabetes Mellitus.
Haruki Imamura,Takashi Yamaguchi,Daiji Nagayama,Atsuhito Saiki,Kohji Shirai,Ichiro Tatsuno (2017). Resveratrol Ameliorates Arterial Stiffness Assessed by Cardio-Ankle Vascular Index in Patients With Type 2 Diabetes Mellitus.
P Usharani,A Mateen,M Naidu,Y Raju,N Chandra (2008). Effect of NCB-02, atorvastatin and placebo on endothelial function, oxidative stress and inflammatory markers in patients with type 2 diabetes mellitus: a randomized, parallel-group, placebo-controlled, 8-week study.
Parviz Khajehdehi,Maryam Pakfetrat,Katayoun Javidnia,Fariborz Azad,Leila Malekmakan,Mahshid Nasab,Gholamreza Dehghanzadeh (2011). Oral supplementation of turmeric attenuates proteinuria, transforming growth factor-β and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: A randomized, double-blind and placebo-controlled study.
Somlak Chuengsamarn,Suthee Rattanamongkolgul,Rataya Luechapudiporn,Chada Phisalaphong,Siwanon Jirawatnotai (2012). Curcumin Extract for Prevention of Type 2 Diabetes.
Na L X 1, Yan B L 2,Jiang S 1, Cui H L 1,Li Y 1,C Sun (2014). Curcuminoids Target Decreasing Serum Adipocyte-fatty Acid Binding Protein Levels in Their Glucose-lowering Effect in Patients with Type 2 Diabetes.
R Neerati P 1, Devde,A Gangi (2014). Evaluation of the effect of curcumin capsules on glyburide therapy in patients with type-2 diabetes mellitus.
Na L X 1,Y Li,H Z Pan,X Zhou,D J Sun,M Meng,X Li,C Sun (2013). Curcuminoids exert glucoselowering effect in type 2 diabetes by decreasing serum free fatty acids: a double-blind, placebocontrolled trial.
Melanie Davies,David D’alessio,Judith Fradkin,Walter Kernan,Chantal Mathieu,Geltrude Mingrone,Peter Rossing,Apostolos Tsapas,Deborah Wexler,John Buse (2018). Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Alan Garber,Martin Abrahamson,Joshua Barzilay,Lawrence Blonde,Zachary Bloomgarden,Michael Bush,Samuel Dagogo-Jack,Ralph Defronzo,Daniel Einhorn,Vivian Fonseca,Jeffrey Garber,W Garvey,George Grunberger,Yehuda Handelsman,Irl Hirsch,Paul Jellinger,Janet Mcgill,Jeffrey Mechanick,Paul Rosenblit,Guillermo Umpierrez (2019). Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2019 Executive Summary.
M Turner (2003). The role of mannose-binding lectin in health and disease.
M Saraheimo,C Forsblom,T K Hansen,A Teppo,J Fagerudd (2005). Increased levels of mannanbinding lectin in type 1 diabetic patients with incipient and overt nephropathy.
X Q Li,M Chang D Y, Chen,M Zhao (2018). Complement activation in patients with diabetic nephropathy.
Xuejing Man,Houliang Zhang,Huajun Yu,Lusheng Ma,Jiangdong Du (2015). Increased serum mannose binding lectin levels are associated with diabetic retinopathy.
Qian Huang,Guilian Shang,Haohua Deng,Jie Liu,Yan Mei,Yancheng Xu (2015). High Mannose-Binding Lectin Serum Levels Are Associated with Diabetic Retinopathy in Chinese Patients with Type 2 Diabetes.
Shi‐qi Zhao,Zhao Hu (2016). Mannose‐Binding Lectin and Diabetic Nephropathy in Type 1 Diabetes.
Ling-Zhi Guan,Qiang Tong,Jing Xu (2015). Elevated Serum Levels of Mannose-Binding Lectin and Diabetic Nephropathy in Type 2 Diabetes.
T K Hansen,L Tarnow,S Thiel,R Steffensen,C Stehouwer (2004). Mannose-binding lectin as a predictor of microalbuminuria in type 1 diabetes: an inception cohort study.
Lianlian Pan,Yali Ye,Mingyi Wo,Danni Bao,Fengjiao Zhu,Maoliang Cheng,Xiuwen Ni,Xianming Fei (2018). Clinical Significance of Hemostatic Parameters in the Prediction for Type 2 Diabetes Mellitus and Diabetic Nephropathy.
Noel Pabalan,Raphael Tiongco,Jefferyl Pandac,Noemi Paragas,Shamar Lasta,Nelven Gallego,Hamdi Jarjanazi,Maria Pineda-Cortel (2016). Association and biomarker potential of elevated serum adiponectin with nephropathy among type 1 and type 2 diabetics: A meta-analysis.
Holman R R,S K Paul,M A Bethel,D Matthews,Haw Neil (2008). 10-year follow-up of intensive glucose controlin type 2 diabetes.
Gall M A 1, Nielsen F S,U Smidt,H Parving (1993). The course of kidney function in type 2 (non-insulindependent) diabetic patients with diabetic nephropathy.

Download References

Funding

No external funding was declared for this work.

Conflict of Interest

The authors declare no conflict of interest.

Ethical Approval

No ethics committee approval was required for this article type.

Data Availability

Not applicable for this article.

How to Cite This Article

Mona M. Salem. 2019. \u201cShould we Change our Therapeutic Management of Type 2 Diabetes based on Accumulating Evidence?\u201d. Global Journal of Medical Research - K: Interdisciplinary GJMR-K Volume 19 (GJMR Volume 19 Issue K5).

More Citation Formats

Select Citation Style:

Download Citation

GJMR Volume 19 Issue K5

Explore Journals Explore Volume Read This Issue

Journal Specifications

Crossref Journal DOI 10.17406/gjmra

Print ISSN 0975-5888

e-ISSN 2249-4618

Keywords

Not Found

Classification

GJMR-K Classification NLMC Code: WD 200

Submission ReceivedDecember 9, 2018
Peer Review Double Blind
Handling Editor
Accepted December 31, 2018
Published January 15, 2019

Version of record

v1.2

Issue date

July 30, 2019

Language

Experiance in AR

Explore published articles in an immersive Augmented Reality environment. Our platform converts research papers into interactive 3D books, allowing readers to view and interact with content using AR and VR compatible devices.

View in VR

Read in 3D

Your published article is automatically converted into a realistic 3D book. Flip through pages and read research papers in a more engaging and interactive format.

View in 3D

Article Matrices

Total Views: 2651

Total Downloads: 1249

2026 Trends

Our website is actively being updated, and changes may occur frequently. Please clear your browser cache if needed. For feedback or error reporting, please email [email protected]